newsfilter
← Latest News
Business Wire·

Sesen Bio Reports Third Quarter 2021 Financial Results and Business Update

Participated in productive CMC Type A Meeting with the FDA Maintained strong balance sheet with $175M in cash and cash equivalents as of September 30, 2021 Sesen Bio (NASDAQ:SESN), a late-stage clinical company developing targeted fusion protein t